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ABSTRACT 
Natural antimicrobial peptides (AMPs) are small cationic molecules that display antimicrobial activity against a wide 
range of bacteria, fungi and viruses. AMPs are multifunctional molecules that have an essential activity in infection and 
inflammation: they play an important role in the innate immune response, not only as antimicrobial agents, but also as 
immunomodulating molecules and as an important link between the innate and adaptive immune response. In this arti-
cle, we will discuss the antimicrobial activity, together with the novel properties of some of these molecules as immune 
modulators on the innate and adaptive immune response. 
 
Keywords: Antimicrobial Peptides; Immune Response; Cathelicidins; Defensins; SLPI 
1. Introduction 
Adaptive immune response is considered critical to pre-
vent the establishment or progression of infections by 
parasites, bacteria and viruses. But it is the innate immu-
nity that is responsible for the rapid initial defense 
against the pathogen. 
The co-evolution of hosts and pathogens has led to a 
diverse group of peptides that the host produces in order 
to kill or reduce the infective microbes. These peptides, 
called antimicrobial peptides (AMPs) can be found in 
almost all forms of life, in organisms like bacteria or 
plants and also in invertebrate and vertebrate species, 
including mammals. Among the latter, humans have sev-
eral cell types that synthesize and secrete AMPs, such as 
epithelial cells, epidermal keratinocytes, neutrophils, 
macrophages, and natural killer cells. In mammals, these 
AMPs can be considered as part of the innate immune 
system.  
Most of the AMPs are generally expressed as pro- 
peptides that undergo subsequent proteolytic process to 
release the biologically active and mature host defense 
peptide. Some AMPs are constitutively expressed but 
others are synthesized upon infection signals such as 
various exogenous and endogenous inflammatory me-
diators [1,2].  
Classically, AMPs are short, amphiphilic, and mostly 
cationic polypeptides with a diverse repertoire of activi-
ties within the innate immunity system. These multifac-
eted molecules may be able to enhance phagocytosis, 
stimulate prostaglandin release, neutralize the septic ef-
fects of LPS, and promote recruitment and accumulation 
of various immune cells at inflammatory sites among 
other functions [3,4]. 
In recent years, these molecules have been the center 
of attention, because of their promising uses as alterna-
tive approaches to infection management.  
AMPs are mainly cationic and amphipathic peptides; 
two characteristics together with their conformational 
flexibility and secondary structure allow them to interact 
with and insert into biomembranes, leading to disruption 
of cytoplasmic membrane integrity. AMPs can also in-
teract with intracellular bacterial targets, resulting in mi-
crobial killing [5]. In general, cationic peptides interfere 
with bacterial membrane integrity such as membrane 
wrinkling and the formation of ion-permeable channels 
that probably increase membrane permeability and fi-
nally lead to bacterial cell lysis. 
It is also worthy to notice that it has recently been 
shown that bacteria are capable of adapting and resisting 
host AMPs, by means of production of peptidases and *Corresponding author. 
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proteases that degrade antimicrobial peptides, or com-
pounds that inhibit their action, and also by reduction of 
net anionic charge of the bacterial cell envelope. The 
relationship between antibacterial peptides and cell wall 
targets may shed light in strategies to challenge antibiotic 
resistance.  
However, even though these host defense peptides 
originally gained prominence through initial descriptions 
of their direct antimicrobial functions [5], not all protec-
tive cationic peptides are necessarily working through 
direct microbicidal action. In contrast, under such condi-
tions, a wide range of functions have been demonstrated 
for these peptides in the context of host immunity, as will 
be discussed in this review.  
Some AMPs are involved in the transition to the adap-
tive immune response, as they were shown to be chemo-
tactic for human monocytes [6], T cells [7], modulating 
dendritic cell differentiation and dendritic cell-induced T 
cell polarization [8]. However, some of them can also 
function as negative feedback regulators facilitating the 
resolution of inflammation [9]. Therefore, it is possible 
that a malfunction of the feedback control, i.e. through a 
decreased secretion of AMPs that participates as negative 
feedback regulator, can amplify and perpetuate the in-
flammatory process.  
As we mentioned, the role of AMPs in innate immu-
nity and the pathogen target has been very well studied, 
but it is less known the ability of them to induce not only 
a T helper cell response, but also an appropriate T cells 
response. This is a very important issue, since an appro-
priate T cell response, i.e. Th1 and Th2 for intracellular 
and extracellular pathogens respectively, will aid the 
resolution or perpetuation of the infection. In this review, 
we have chosen only three AMPs: cathelicidins, de-
fensins and SLPI, to describe the typical functions and to 
illustrate their ability to modulate the immune response. 
2. AMPs Categories 
Host defense peptides can be organized into three basic 
categories regarding the target: 1) plasma membrane- 
active peptides are thought to act in a multistage process 
where they electrostatically bind to a membrane surface, 
aggregate to form superstructures, and disrupt membrane 
integrity; 2) a second group of peptides act on intracellu-
lar targets to inhibit transcriptional, translational or other 
processes; and 3) cell wall-active peptides target precur-
sors, mechanisms, and/or essential intermediates in pep-
tidoglycan, lipopolysaccharide (LPS) or other biosyn-
thetic pathways interfering with functional cell wall syn-
thesis and ensuing bacterial replication. 
3. Eukariotic Peptides 
When the first eukaryotic defensin peptides were charac-
terized nearly 30 years ago, mechanism of action studies 
indicated that these molecules were able to rapidly and 
efficiently permeabilize artificial membrane bilayers 
[10]. 
Eukaryotic peptides are typically small and cationic, 
and are structurally classified into five major groups: 1) 
cysteine-stabilized (e.g., defensins); 2) cysteine-stabi- 
lized loop (e.g., protegrins, tachyplesins); 3) linear α- 
helical (e.g., LL-37, kinocidin helices); 4) enriched in 
one or more specific amino acid residues (i.e., Bac5); or 
5) combinations of the above. Although certain families 
of host defense peptides, particularly those of higher eu-
karyotes, show evidence of extensive gene duplication, 
and in some cases positive selection, their structural 
(cysteine stabilization, α-helicity) and biophysical (am-
phipathicity, cationicity) features are often highly con-
served. 
4. Defensins 
Defensins are cationic AMPs produced at a variety of 
epithelial surfaces by various cells as a component of the 
innate host defense. They are cyclic peptides which are 
categorized into three subfamilies on the basis of the di-
sulfide pairings between their six conserved cysteine 
residues (α- and β-defensins) or their macrocyclic nature 
(θ-defensins). The α- and β-defensins are widely distrib-
uted in vertebrate species, whereas θ-defensins have so 
far been identified only in Old World monkeys and ap-
parently only in neutrophils and monocytes [11,12]. In 
mammalian species, around 50 α-defensins and 90 β- 
defensins have been identified which are either stored in 
the granules of neutrophils and Paneth cells, or are gen-
erated by monocytes/macrophages, keratinocytes or 
epithelial cells of the respiratory, digestive, urinary and 
reproductive systems [13,14]. 
α- and β-defensins modify cell migration and matura-
tion, induce cytokines and trigger histamin and pros-
taglandin D2 release from mast cells. β-defensins are 
chemoattractive for immature dendritic cells and memory 
T cells. 
The production of defensins is regulated by pathogens 
or by inflammatory cytokines released at the site of in-
flammation. For example, alpha-defensins can be re-
leased upon microbial invasion or up-regulated by 
stimulation with lipopolisaccharides and tumor necrosis 
factor- [15]. The β-defensins, found in epithelial cells 
as well as monocytes/macrophages and dendritic cells, is 
up-regulated in bacterial infections through the recogni-
tion of bacterial components by the Toll-like receptor 
(TLR) [16-19]. The production and secretion can be also 
modulated by other AMPs. For example, the human 
cathelicidin LL37 can synergize with IL-1β to increase 
the production of IL-6, IL-8, IL-10, CCL2, as well as to 
increase the synthesis and release of α-defensins [20,21]. 
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On the contrary, downregulation of defensins can be in-
duced by endogenous glucocorticoids leading to in-
creased severity of group A Streptococcus pyogenes skin 
infection [22]. It was also demonstrated that the inactiva-
tion of the antimicrobial activity of β-defensins contrib-
utes with the recurrent airways infections in patients with 
cystic fibrosis [23,24].  
The antimicrobial activity of defensins has been de-
termined in Staphylococcus aureus, Pseudomonas aerugi-
nosa, Salmonella and certain enveloped viruses [25,26]. 
This antimicrobial function is supported by experiments 
performed in knocking-out β-defensin 1 mice [27]. 
AMPs constitute a substantial part of the mucosal bar-
rier, and β-defensins are the principal type secreted by 
the epithelium. The four well-characterized human β 
defensins, hBD-1-4, encoded by β-defensin 1 (DEFB1), 
DEFB4, DEFB103, and DEFB104, are small (30 - 47 
amino acid), cationic, cysteine-rich peptides that possess 
broad antimicrobial activity [28].  
The antimicrobial activity is potentiated under reduc-
ing conditions that exist in the hypoxic gut lumen, 
whereas other antimicrobial peptides, such as hBD-3, are 
diminished in the reduced state. 
The expression of hBD-1 is constitutive, whereas other 
defensins are expressed in response to microbial and in-
flammatory stimuli. Defective expression of hBD-1 is 
associated with mucosal diseases, such as inflammatory 
bowel disease, candidia carriage, periodontitis, and den-
tal carries. 
DEFB114 is a β defensin that exhibited a broad spec-
trum of antimicrobial activity against typical pathogenic 
microbes. This AMP also demonstrated to have LPS 
binding activity while inhibiting the release of TNF-α in 
RAW264.7 culture when challenged with LPS through 
the inhibition of MAP kinase p42/44. This peptide also 
displayed antimicrobial activity against typical pathogens, 
i.e., Escherichia coli, Staphylococcus aureus, and Can-
dida albicans, while showing low cytotoxicity toward 
human erythrocytes. All these features are indicative of 
its potential therapeutic use in the treatment of LPS-in- 
duced inflammation [29]. 
Besides inhibiting microbial growth, an additional 
function of some of these AMPs is their influence on the 
immune response by recruiting leukocytes through the 
induction of chemokines such as CXCL8 (IL-8), CCL2 
(MCP-1), IP-10, MIP3α, RANTES and cytokines such as 
IL-6, IL-10, IL-18, IFNγ and IFN-α. Cells that can be 
recruited and activated by defensins are neutrophils, 
monocytes, macrophages, immature dendritic cells, mast 
cells and T cells [30-32]. Therefore, defensins can tailor 
the adaptive immune response even by inducing the ex-
pression of the costimulatory molecules CD80, CD86 
and CD40 on monocytes and dendritic cells [31]. 
Antigen specific cytotoxic T lymphocytes can be in-
duced by -defensins and murine -defensins, thereby 
enhancing Th1-dependent cellular responses, and poten-
tially anti-tumour immunity [33,34].  
However, systemic injections of human α defensins 
into mice result in augmentation of both Th1 and Th2 
immune responses [35]. Whether human β defensin also 
induce a Th1 and Th2 immune response it is less known 
since human β defensins are inactive in mice. Experi-
ments with murine β defensins (MBDs) in mice suggest 
that these defensins induce mainly a Th1 response [36]. 
On the other hand, it was shown that human defensins 
co-administered with antigens in mice resulted in an in-
creased production of antibodies, providing evidence of 
the role of these peptides in humoral response [37]. Other 
functions of defensins have been deeply discussed by 
Oppenheim [36]. Based on these findings, it seems that 
the action of defensins on T cell responses is not specific, 
since these peptides enhance both cellular and humoral 
cytokine production and immune responses. 
As it was mentioned above, a less beneficial effect of 
β-defensins is also suggested, since β-defensins could 
amplify inflammation by binding CCR6 expressed by 
Th17 cells [38,39]. 
In 2008, a study by Sass et al. [40], evaluated the anti-
biotic mode of action of β-defensin (hβD-3) against 
Staphylococcus aureus. They showed that hβD-3 induces 
alterations in the S. aureus core cell wall stress regulon in 
a similar fashion to the cell wall-active antibiotic van-
comycin. This observation is consistent with the concept 
that hβD-3 perturbs specific component(s) of the cell 
wall, triggering upregulation of cell wall stress response 
pathways. Further, hβD-3 inhibits purified enzymes re-
quired for cell wall synthesis. Finally, transmission elec-
tron microscopy revealed that exposure to hβD-3 causes 
apparent fissures in the cell wall that allowed for protru-
sions of membrane bound cytoplasmic contents of S. 
aureus.  
5. Cathelicidin 
The name cathelicidin comes from the highly conserved 
N-terminal region of these proteins known as the cathelin 
domain. This protein contains two disulfide bonds be-
tween cysteine residues C85-C96 and C107-C124 [41] 
and was given its name based on an ability to inhibit the 
protease cathepsin-L. The cathelicidin LL-37 is the only 
member of the cathelicidin family expressed in humans 
[42]. 
The main source of cathelicidin in the human body is 
azurophilic granules of neutrophil, but it can also be 
found in mucosal surfaces and in keratinocytes during 
inflammation [42]. Another study also demonstrated the 
increased expression of LL-37 in macrophages, endothe-
lial cells and T cells in atherosclerotic lesions [43].  
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Unlike defensins, cathelicidin expression in humans is 
less directly modulated by TLRs or cytokines, but rather 
relies on the action and modulation of Vitamin D in 
specific tissues [44].   
Like other AMPs, cathelicidins kill bacteria through 
permeabilization of bacterial cell membranes and binding 
to LPS [45]. The microbicidal activity of cathelicidin was 
further supported by in vivo experiments with catheli-
cidin knockout mice [46]. Furthermore, cathelicin LL-37 
acts on mast cells and increases the expression of TLR4, 
while releasing histamine, prostaglandins and the cyto-
kines IL-4, IL-5, IL-1β [47] and IL-8 in airway epithelial 
cells and keratinocytes [48]. Thus, it acts as a chemokine 
for neutrophils, monocytes, mast cells and T cells but not 
for dendritic cells [49]. Cathelicidin also suppresses neu-
trophil apoptosis, and on the other hand promotes apop-
tosis of epithelial cells [49].  
It has been demonstrated that LL-37 is a potent modi-
fier of DC differentiation. LL-37-derived DC displayed 
significantly up-regulated endocytic capacity, modified 
phagocytic receptor expression and function, up-regu- 
lated co stimulatory molecule expression, enhanced se-
cretion of Th-1 inducing cytokines, and promoted Th1 
responses in vitro [50].  
However, Kandler et al. showed that LL-37 sup-
pressed the maturation and activation of human dendritic 
cells in response to a number of TLR ligands and thus the 
ex vivo costimulation of T cells [51]. Furthermore, LL-37 
increased the level of TLR4 and induced the release of 
Th2 cytokines IL-4, IL-5 and IL-1β from mast cells [47]. 
Besides, LL37 synergistically enhances the IL-1β in-
duced production of cytokines (IL-6, IL-10) and chemoki-
nes such as MCP-1 and MCP-3 in human peripheral 
blood monocytes [20]. These findings suggest that LL-37 
induces mainly a Th2 response. 
So far, there is no data on LL-37 and the induction of 
Th17, although Peric, M. et al. [52] reported that human 
keratinocytes could increase the expression of catheli-
cidin when stimulated in the presence of vitamin D(3) 
and this increase was signaled through the IL-17RA.  
The hCAP-18 prepropeptide is mainly produced in 
leucocytes and epithelial cells. After secretion, process-
ing to the active AMP occurs by local proteases. As the 
proteolytic activity of various cells and tissues differs, 
hCAP-18 can be processed either to the full-length active 
peptide LL-37 found in the exocytosed material of neu-
trophils or to multiple smaller peptides such as RK-31 
and KS-30, which occur on the skin surface and display 
increased antimicrobial activity.  
In neutrophils, hCAP-18 is stored in the specific gran-
ules and, upon degranulation, is processed to LL-37 by 
protease 3 released from the azurophilic granules. In the 
skin, RK-31 and KS-30 are produced by the action of 
SCTE (stratum corneum tryptic enzyme, kallikrein 5/hK5) 
and SCCE (stratum corneum chymotryptic enzyme, kal-
likrein 7/hK7). High concentrations of hCAP-18 are pre-
sent in seminal plasma. Proteolytic cleavage by semen- 
derived gastricsin occurs when the pH drops in the va-
gina generating the active peptide ALL-38. Similar to the 
defensins, cathelicidin peptides exert various immuno-
modulatory functions. As a striking example for the im-
portance of cathelicidin for human health, LL-37 defi-
ciency was found to be associated with chronic peridon-
tal disease. High levels of hCAP-18/LL-37 are produced 
in healing human skin suggesting an important role in 
re-epithelialization during wound healing. 
Consistently, healing was inhibited by LL-37 specific 
antibodies in an organ-cultured human skin model and in 
chronic ulcers, hCAP-18/LL-37 was found to be absent 
in ulcer edge epithelium. 
Although not a direct measure of microbicidal activity, 
numerous studies have demonstrated that LL-37 binds 
LPS with high affinity [53-55] and hence may limit its 
endotoxic properties as well as downstream immu-
nological signaling events.  
In Gram negative bacteria, resistance to cationic an-
timicrobial peptides is conferred via activation of PhoP/ 
PhoQ and PmrA/PmrB two component regulatory sys-
tems, which lead to increased incorporation of positively 
charged l-4-aminoarabinose subunits into LPS and other 
adaptive responses [56]. This molecular modification 
results in a more neutral or even cationic surface charge, 
and hence reduced electrostatic attraction for cationic 
antimicrobial peptides, affording increased survival of 
organisms. 
Although the above studies are not a direct measure of 
LL-37’s mechanism of action, they do suggest that mem-
bers of this classical α-helical host defense peptides fam-
ily may have specific interactions with certain Gram- 
negative cell wall component structures. 
6. SLPI 
Secretory Leukocyte Protease Inhibitor (SLPI) is a serine 
protease inhibitor of cathepsin G, trypsin and chy-
motrypsin, but primarily against neutrophil elastase [57]. 
SLPI was first isolated from bronchial secretions and was 
later found to be also produced by many mucosal sur-
faces, keratinocytes, neutrophils and macrophages. 
This polycationic non-glycosylated peptide display an-
timicrobial properties in vivo and in vitro [58,59]. The 
antimicrobial activity of human SLPI has been described 
for Escherichia coli, Pseudomonas aeruginosa, Staphy-
lococcus aureus, Staphylococcus epidermidis, Strepto-
coccus sp., Aspergillus fumigatus, Candida albicans, and 
HIV [58]. It has been recently reported that mouse and 
even human SLPI shows antibacterial activity against 
mycobacteria and it constitutes a pattern recognition re-
ceptor for mycobateria that not only kills bacteria but  
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facilitates their phagocytosis by murine and human 
macrophages [60]. The antimycobacterial activity of 
SLPI resides in the WAP (Whey Acidic Protein) domains 
of the molecule and is quite similar to other cationic pep-
tides [61]. The antimicrobial activity clearly does not 
depend on inhibition of serine proteases. Instead, disrup-
tion of the membranes of target organisms is observed, 
most likely depending of the cationic nature of these 
small proteins. 
As it was mentioned before, SLPI is constitutively pro-
duced by epithelial cells and neutrophils and alveolar 
macrophages. Its expression is upregulated by diverse 
inflammatory stimuli such as TNFα and M. tuberculosis 
and downmodulated by adenoviral infection, TGFβ1 cy-
tokine production and during chronic obstructive lung 
disease [62-67]. In a recent review, the multifaceted roles 
of SLPI and elafin/trappin-2 were examined in the con-
text of their possible use as inhaled drugs for treating 
chronic lung diseases such as CF (cystic fibrosis) and 
COPD (chronic obstructive pulmonary disease) [68].  
6.1. SLPI as a Biomarker 
Jendeberg et al. measured the antimicrobial peptide con-
centration in plasma from patients with community-ac- 
quired pneumonia (CAP), in this work the authors found 
that in subjects with CAP, mean plasma concentrations 
of SLPI and bactericidal/permeability-increasing protein 
(BPI) were significantly higher than in healthy control 
subjects, but less markedly increased in patients with 
non-respiratory tract infections. The finding of higher 
SLPI levels in male subjects with CAP implies that there 
are sex-dependent immunological differences in SLPI 
turnover [69]. 
The relationships between rhinovirus infection and 
bacterial infection and the role of antimicrobial peptides 
in COPD exacerbations were also investigated. In this 
studies the antimicrobial peptides SLPI, elafin, pentraxin, 
LL-37, α-defensins and β-defensin-2, and the protease 
neutrophil elastase were evaluated. The authors con-
cluded that neutrophil elastase was significantly in-
creased and SLPI and elafin significantly reduced after 
rhinovirus infection exclusively in subjects with COPD 
with secondary bacterial infections, and SLPI and elafin 
levels correlated inversely with bacterial load. Rhinovi-
rus infections are frequently followed by secondary bac-
terial infections in COPD and cleavage of the antimicro-
bial peptides SLPI and elafin by virus-induced neutrophil 
elastase may precipitate in these secondary bacterial in-
fections. Therapy targeting neutrophil elastase or en-
hancing innate immunity may be useful novel therapies 
for prevention of secondary bacterial infections in virus- 
induced COPD exacerbations [70]. 
6.2. SLPI as Anti-Inflammatory Molecule 
Besides the antimicrobial activity, SLPI major function is 
to inhibit inflammation by blocking the proteolitic activ-
ity of serine proteinases released by leukocytes and also 
through downmodulating several cytokines up-regulated 
via LPS such as TNFα, MCP-1 and IL-6 [71-75]. 
The anti-inflammatory activity is also mediated by in-
hibition of proteolitic degradation of IkB and the activa-
tion of the transcription factor nuclear factor NFkB [75, 
76]. Moreover, SLPI knock out mice show impaired cu-
taneous wound healing with increased activation of local 
TGFβ [77]. 
The role of SLPI in adaptive immunity is less clear. 
Samsom et al. proposed that SLPI expression in dendritic 
cells located in cervical lymph node contributes to mu-
cosal tolerance [78]. Furthermore, SLPI modulates anti-
body class switching by dampening IgG and IgA class 
switching recombination without affecting B cell prolif-
eration [79]. However, splenic B cells from SLPI knock 
out mice have higher proliferation rates and produce 
higher levels of IgM [80]. Overall these data indicate that 
SLPI may affect adaptive immune response, however, it 
is not known whether SLPI might affect directly the 
classical Th1 or Th2 pattern of cytokines.  
Another serine protease inhibitor of the same family of 
SLPI, named ELAFIN, can activate lung dendritic cells 
and produce a bias to Th1 response, in an in vivo murine 
model [81]. Moreover, it was suggested that SLPI could 
also favour a Th1 response, since SLPI can inhibit 
LPS-induced production of PGE2 from monocytes and 
PGE2 skews T-helper lymphocyte cytokine production 
towards a Th2 immune response [82]. However, this data 
does not agree with the suppression of inflammation ob-
served in an arthritis mouse model [83]. The activity of 
SLPI on adaptive immune response seems to be complex. 
It was observed that SLPI-treated human peripheral 
mononuclear cells may release Th2 cytokines. Therefore, 
further studies are required to clarify the role of SLPI in 
T helper cells immune response. 
Although not yet understood in detail, SLPI was dem-
onstrated to be a pivotal endogenous factor necessary for 
optimal cutaneous and mucosal wound healing, most 
likely due to its antiprotease activity [77,84,85]. 
6.3. SLPI in HPV and HIV Infection 
Hoffmann, M., et al demonstrated that exposure of hu-
man cervical epithelial cells to high-risk human papillo-
maviruses results in a reduction in the expression of SLPI 
[86]. In head and neck squamous cell carcinoma 
(HNSCC) tissue, HPV DNA was analyzed and correlated 
with SLPI expression. A possible role of smoking on 
SLPI expression in clinically normal mucosa was also 
investigated, 19 patients treated for non-malignant dis-
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eases (non-HNSCC) were analyzed for SLPI expression 
and correlated with smoking habits. In HNSCC patients, 
SLPI expression showed a significant inverse correlation 
with HPV status. For the first time, a correlation between 
SLPI downregulation and HPV infection was demon-
strated, suggesting that high levels of SLPI, possibly in-
duced by environmental factors such as tobacco smoking, 
correlate with protective effects against HPV infection 
[87]. 
Depressed cervicovaginal SLPI levels have been cor-
related with Trichomonas vaginalis infection. SLPI lev-
els were lower in females with a positive T. vaginalis 
antigen test result, a vaginal pH > 4.5, vaginal leukocyto-
sis, and recurrent T. vaginalis infection. SLPI level was 
reduced by >50% in a T. vaginalis load-dependent man-
ner. The SLPI level could be used as a vaginal-health 
marker to evaluate interventions and vaginal products 
[88]. 
SLPI was identified as a factor responsible for selec-
tive anti-HIV activity of human saliva [89]. It appears 
that this activity results from binding of SLPI to host cell 
membrane associated proteins such as scramblase and/or 
annexin II, rather than direct interaction with the virus 
particle [90,91]. SLPI have also been associated with 
anti-HIV activity of vaginal fluid [92,93]. Mechanisti-
cally, SLPI has been shown to inhibit HIV-1 infection of 
macrophages by binding to and blocking cell surface 
annexin A2 [34]. Annexin A2 is found at the cell surface 
as the annexin A2 heterotetramer (A2t) consisting of two 
annexin A2 monomers and an S100A10 dimer [94,95], 
which are co-expressed by basal epithelial cells [96]. It 
was also demonstrated that the annexin A2 hetero-
tetramer (A2t) contributes to HPV16 (the most common 
high-risk genotype) infection and co-immunoprecipitates 
with HPV16 particles on the surface of epithelial cells in 
an L2-dependent manner. Inhibiting A2t with an en-
dogenous annexin A2 ligand, SLPI, or with an annexin 
A2 antibody significantly reduces HPV16 infection [97].  
6.4. SLPI as a PRR 
The innate immune system of the host is able to detect 
“pathogen-associated molecular patterns” (PAMPs), con-
served molecular structures produced exclusively by mi-
croorganisms that are essential for the physiology of mi-
crobes [98]. PAMPs are recognized by pattern recogni-
tion receptors (PRRs) of the host. Some of them, like 
TLR2 and TLR4, are present on the cell surface of cells 
from the innate immune system, in contrast, other PRRs, 
like TLR3 and TLR7, are found inside the cells. Finally, 
the last group of known PRRs, such as surfactants and 
C-reactive protein, are soluble and present in extracellu-
lar body fluids. The recognition of PAMPs by PRRs fa-
cilitates the uptake of the pathogen or the signaling 
needed for the induction of the appropriate immune re-
sponse of the host [98,99]. AMPs are able to bind and 
kill a pathogen but it is not clear whether most of these 
peptides could be considered as a PRR, specifically 
binding to PAMPs and facilitating the clearing by 
macrophages. Gomez et al. [59] demonstrated that hu-
man recombinant SLPI not only kills mycobacteria but 
also acts as a pattern recognition receptor for the host 
immune system. 
7. Conclusions 
There is no doubt that AMPs have a microbicidal activity 
and a role in modulating the immune response. Moreover, 
some of them, like SLPI, acts like pattern recognition 
receptors that facilitate the clearing of the pathogens by 
immune cells. 
Therefore, in the era of antibiotic resistance they look 
as excellent candidates to develop new antimicrobial 
agents. However, they may elicit an array of different 
actions on adaptive immune response that it has to be 
determined before the new drugs become available. The 
activities of these peptides should be analyzed under dif-
ferent physiological and pathological settings, since the 
activity may vary depending on the immune response 
elicited by the pathogen.  
Understanding these pleiotropic molecules that func-
tion as “natural antibiotics” and “immune regulators” has 
great promise for yielding new strategies in the control of 
human disease. 
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